Sensitivity and specificity
Sensitivity is the share of people with the disease a test catches; specificity is the share of healthy people it correctly clears. No test scores 100% on both, and for screening the trade-off decides how many false alarms you get.
Overview
Sensitivity (true-positive rate) and specificity (true-negative rate) are properties of the test at a chosen cut-off and are usually estimated against a reference standard such as colonoscopy or biopsy in a study like ECLIPSE or BLUE-C. What a person experiences, the chance that a positive result is real, is the positive predictive value, which depends on how common the disease is: at a 1% cancer prevalence, a test with 99% specificity still generates about as many false positives as true positives. Screening tests trade sensitivity against specificity by moving the cut-off; a multi-cancer blood test set to high specificity (99.5% for Galleri) accepts low sensitivity for early-stage cancer. Sensitivity for precancerous lesions, not cancer, is what distinguishes tests that prevent colorectal cancer from tests that detect it.
Pages like this
not linked directly; found by shared links- ProductCologuard
Shares DeeP-C, Cologuard Plus, Positive predictive value (PPV), Screening.
- TermFaecal immunochemical test (FIT)
Shares BLUE-C, DeeP-C, Cologuard Plus.
- ProductShield
Shares ECLIPSE (Shield blood test), Cologuard Plus, SimpleScreen CRC, Screening.
- TechnologyColorectal cancer screening (colonoscopy, FIT, stool DNA, blood)
Shares BLUE-C, DeeP-C, ECLIPSE (Shield blood test), Cologuard Plus.
- TrialTMIST (Tomosynthesis Mammographic Imaging Screening Trial)
Shares Overdiagnosis, Screening.
- TechnologySkin cancer screening (visual skin examination)
Shares Overdiagnosis, Screening.
- TermCell-free DNA (cfDNA)
- ProductCancerguard
Shares Positive predictive value (PPV), Screening.